Version 1
: Received: 3 June 2024 / Approved: 3 June 2024 / Online: 3 June 2024 (09:51:47 CEST)
How to cite:
Salama, R. A. A.; Patni, M. M.; Ba-Hutair, S. N. M.; Wadid, N. A.; Akikwala, M. S. Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges. Preprints2024, 2024060058. https://doi.org/10.20944/preprints202406.0058.v1
Salama, R. A. A.; Patni, M. M.; Ba-Hutair, S. N. M.; Wadid, N. A.; Akikwala, M. S. Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges. Preprints 2024, 2024060058. https://doi.org/10.20944/preprints202406.0058.v1
Salama, R. A. A.; Patni, M. M.; Ba-Hutair, S. N. M.; Wadid, N. A.; Akikwala, M. S. Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges. Preprints2024, 2024060058. https://doi.org/10.20944/preprints202406.0058.v1
APA Style
Salama, R. A. A., Patni, M. M., Ba-Hutair, S. N. M., Wadid, N. A., & Akikwala, M. S. (2024). Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges. Preprints. https://doi.org/10.20944/preprints202406.0058.v1
Chicago/Turabian Style
Salama, R. A. A., Nihal Amir Wadid and Mushirabanu Sharifmiyan Akikwala. 2024 "Novel Treatment Modalities of Type 1 Diabetes Mellitus: Opportunities and Challenges" Preprints. https://doi.org/10.20944/preprints202406.0058.v1
Abstract
Despite the effectiveness of insulin injections in managing hyperglycemia in Type 1 Diabetes, they fall short in addressing autoimmunity and regenerating damaged islets. This review aims to explore the potential of various treatment modalities for T1DM, including mesenchymal stem cells (MSCs), MSC-derived exosomes, gene therapy, islet allotransplantation, and pancreatic islet cell transplantation. Results: MSCs demonstrate efficacy in T1DM treatment through immunomodulation and tissue regeneration, although further research is warranted to optimize their therapeutic potential. Gene therapy presents a promising approach despite challenges such as donor shortage and immune rejection. Pancreatic islet cell transplantation emerges as a viable option, albeit with associated risks including graft rejection and the need for immunosuppression. Teplizumab, an FDA-approved humanized monoclonal antibody, revolutionizes the treatment landscape of Type 1 Diabetes by significantly delaying its onset, offering a paradigm shift since the discovery of insulin Conclusion: Ongoing studies and technological advancements in T1DM management offer a promising outlook for improved treatments and possibly even eradication on a global scale. MSCs, MSC-derived exosomes, gene therapy, and pancreatic islet transplantation hold considerable potential.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.